Video
CLL at ASH: A ‘mountain of data’ for targeted therapies
SAN DIEGO – Dr. Brian Hill and Dr. Anthony Mato break down the take-home points from the key studies on chronic lymphocytic leukemia presented at...
Video
Social media can help doctors stay up to date
SAN DIEGO – Dr. Amber Yates said being active on Twitter has helped her streamline the journals she reads.
Video
LCAR-B38M CAR T therapy appears durable in myeloma
SAN DIEGO – Positive phase 1 results keep LCAR-B38M in the CAR T race in multiple myeloma.
Video
FLT3 inhibitor moves forward in newly diagnosed AML
SAN DIEGO – Dr. Keith W. Pratz reviewed results from a phase 1 study of gilteritinib and next steps in newly diagnosed patients.
Video
Beat AML trial delivers genomic results in 7 days
SAN DIEGO – The umbrella trial, sponsored by the Leukemia & Lymphoma Society, harnesses technology to speed genomic results that could...
News
Opioids appear safe for sickle cell pain
SAN DIEGO – For sickle cell patients, opioid-related mortality is essentially a “never” event.
Video
New treatments promise sickle cell “cure” for all ages
SAN DIEGO – Dr. Ify Osunkwo described the latest approaches, from gene therapy to haploidentical stem cell transplant, as well as patient access...
News
Bortezomib may overcome resistance in WM
Bortezomib may help overcome treatment resistance in patients with Waldenström’s macroglobulinemia (WM) and CXCR4 mutations, according to a new...
News
NHL patients report fear, isolation during chemo
The qualitative study found that patients reported feeling like they were on an “emotional roller coaster” during their treatment.
News
Bortezomib may unlock resistance in WM with mutations
The study tested how a bortezomib treatment combination would perform in patients with CXCR4 mutations.
News
Study challenges LVEF assessment before DLBCL treatment
Preliminary findings have researchers questioning why cardiac testing is routine before administering chemotherapy containing doxorubicin.
News
Ibrutinib discontinuation harms survival in CLL
A single-institution study examines the impact of early dose reduction of ibrutinib in non-Hodgkin lymphoma and CLL.
News
Ibrutinib plus obinutuzumab gets priority review in CLL/SLL
This sets the stage for
News
Entospletinib falls short in relapsed/refractory DLBCL
The oral, selective inhibitor of spleen tyrosine kinase had a high rate of adverse events and treatment interruption in the phase 2 study.